Editorials

All That Glitters Is Not Gold — Standardizing Diagnosis in Rheumatoid Arthritis Studies .......................... 1223
K.P. Liao, V. Bykerk, et al

Who's Holding up the Queue? Delay in Treatment of Rheumatoid Arthritis .............................. 1225
J.E. Homik

Rehabilitation for Ankylosing Spondylitis in the Era of Biologics: Any Room Left for This Treatment? 1228
E. Lubrano, C. Palazzi, I. Olivieri

Should Clinicians Start Measuring Flow Mediated Dilation Response in Patients with Systemic Lupus Erythematosus? 1231
C.S. Lau

Review

Challenges in Diagnosing Latent TB Infection in Patients Treated with TNF Antagonists .......................... 1234
E.C. Keystone, K.A. Papp, W. Wobeser

Articles

Lymphotoxin-α 252 A>G Polymorphism: A Link Between Disease Susceptibility and Dyslipidemia in RA? 1244

Diagnostic Accuracy of ACR/EULAR 2010 Criteria for RA in a 2-Year Cohort ........................................ 1250
S. Varache, D. Cornec, J. Morvan, et al

Incidence and Risk Factors for Serious Infection in Patients with RA Treated with TNF Inhibitors: A Report from the Registry of Japanese RA Patients for Longterm Safety 1258
Y. Komano, M. Tanaka, T. Nanki, et al, for the REAL Study Group

A Comparison Between IgG- and IgA-class Antibodies to CCP and to Modified Citrullinated Vimentin in Early RA and Very Early Arthritis ....................................................... 1265
A. Svärd, A. Kastbom, M.K. Söderlin, Å. Reckner-Olsson, T. Skogh

Persistence with Anti-TNF Therapies in Patients with RA: Observations from the RADIUS Registry 1273
J.A. Markenson, A. Gibofsky, W.R. Palmer, et al

Time to Treatment for New Patients with RA in a Major Metropolitan City ........................................... 1282
S. Jamal, S.M.H. Alibhai, E.M. Badley, C. Bombardier

Prognostic Indicators of Hospitalized Patients with SLE: A Large Retrospective Multicenter Study in China 1289
X. Feng, Y. Zou, W. Pan, et al

Endothelium-dependent But Not Endothelium-independent Flow-mediated Dilation Is Significantly Reduced in Patients with SLE without Vascular Events: A Metaanalysis and Metaregression 1296
A. Mak, Y. Liu, R.C-M Ho

Longterm Followup After Tapering MMF During Maintenance Treatment for Proliferative Lupus Nephritis 1304
K. Laskari, A.G. Tzioufas, A. Antoniou, H.M. Moutsopoulos

Quantitative Data for Care of Patients with SLE in Usual Clinical Settings: A Patient Multidimensional HAQ and Physician Estimate of Noninflammatory Symptoms 1309
A.D. Askarane, I. Castrejón, T. Pincus

Late-age Onset SSc 1317
R.L. Manno, F.M. Wigley, A.C. Gelber, L.K. Hummers

Expert Agreement on EULAR/EUSTAR Recommendations for the Management of SSc 1326
K.M. Walker, J. Pope, on behalf of the Scleroderma Clinical Trials Consortium and the Canadian Scleroderma Research Group

Malignancies in Italian Patients with SSc Positive for Anti-RNA Polymerase III Antibodies 1329
S. D’Angelo, A. Spadaro, C. Palazzi, I. Olivieri

Rehabilitation Treatment in Patients with AS Stabilized with TNF Inhibitor Therapy. A Randomized Controlled Trial 1335
S. Masiero, L. Bonaldo, M. Pigatto, A. Lo Nigro, R. Ramonda, L. Punzi

The SPARCC Registry for SpA 1343

Resolution of Inflammation Following Treatment of AS Is Associated with New Bone Formation 1349

Effectiveness and Safety of Etanercept in Patients with PsA in a Canadian Clinical Practice Setting: The REPARe Trial 1355

High Prevalence of Subclinical Left Ventricular Dysfunction in Patients with PsA 1363

Prevalence of Thyroid Autoimmunity in Patients with SpA 1371

Candidate Genes in Patients with Autoinflammatory Syndrome Resembling TNF Receptor-associated Periodic Syndrome Without Mutations in the TNFRSF1A Gene 1378
S. Borghini, M. Fiore, M. Di Duca, et al
Febuxostat in Gout: Serum Urate Response in Uric Acid Overproducers and Underexcretors D.S. Goldberg, P.A. MacDonald, B. Hunt, L. Gunawardhana .......................... 1385


Longterm Therapeutic Response to Milnacipran Treatment for FM: A European 1-Year Extension Study Following a 3-Month Study J.C. Branco, P. Cherin, A. Montagne, A. Bouroubi, on behalf of the Multinational Coordinator Study Group. .............. 1403


Pediatric Rheumatology

Heterotopic Ossification of the TMJ in JIA S. Ringold, M. Thapa, E.A. Shaw, C.A. Wallace ................. 1423

MBL Expression Genotype in Pediatric-onset SLE: Associations with Susceptibility to Renal Disease and Protection Against Infections Y-C. Tsai, K-W. Yeh, T-C. Yao, Y-L. Huang, M-L. Ku, J-L. Huang ............. 1429


Development of IBD in Patients with JIA Treated with Etanercept T.D. van Dijken, S.J. Vastert, V.M. Gerloni, et al .................. 1441

Images in Rheumatology

Fluorescence Optical Imaging of Juvenile Arthritis S.G. Werner, H-E. Langer, G. Horneff ................................................. 1447

OMERACT 10

10th International Consensus Conference on Outcome Measures in Rheumatology Kota Kinabalu, Borneo - May 4-8, 2010

Introduction ................................................................. 1448

Disease-specific Outcomes


Tophus Measurement as an Outcome Measure for Clinical Trials of Chronic Gout: Progress and Research Priorities N. Dalbeth, F.M. McQueen, J.A. Singh, et al .......................... 1458

Serum Urate in Chronic Gout — Will It Be the First Validated Soluble Biomarker in Rheumatology? L.K. Stamp, P.P. Khanna, N. Dalbeth, et al ............................................. 1462


Toward Development of a FM Responder Index and Disease Activity Score: OMERACT Module Update P.J. Mease, D.J. Clauw, R. Christensen, et al, and the OMERACT Fibromyalgia Working Group ..................... 1487


Endorsement of Definitions of Disease Activity States and Improvement Scores for the AS Disease Activity Score: Results from OMERACT 10 P.M.M.C. Machado, R.B.M. Landewé, D.M. van der Heijde ........................................ 1502


Developing Disease Activity and Response Criteria in CTD-related IBD L.A. Saketkoo, E.L. Matteson, K.K. Brown, J.R. Seibold, V. Strand; for the Connective Tissue Disease-related Interstitial Lung Disease Special Interest Group ..................................................... 1514

Correspondence

Where in the World is Oral Triamcinolone? L. Roger .......................... 1519

Reply R. Aiten .............................................................. 1519

Lupus Related Longitudinal Myelitis D.M. Wingerchuk, B.G. Weisman ......................................................... 1520

Reply P. Zotos ............................................................ 1520


Who Discovered the ESR? A. Grzybowski, J.J. Sak .......................... 1521

Reply E.L. Matteson, C.S. Crowson ........................................ 1523

Letters


Acute Presentation of Tophaceous Myelopathy E. Levin, K. Hurth, R. Joshi, R. Brasington ........................................ 1525

AS Refractory to TNF Blockade Responds to Tocilizumab J-D. Cohen, R. Ferreira, C. Jorgensen .......................... 1527

Positive C-ANCA with PR3 Specificity Glomerulonephritis in a Patient with Subacute Bacterial Endocarditis M. Uh, I.A. McCormick, J.T. Kelsall .......................... 1528

Primary Aldosteronism Simulating Polymyositis Y-C. Tang, S-K. Wang, W-L. Yuan ......................................................... 1529

Corrections

Intraarticular Botulinum Toxin A for Refractory Painful Total Knee Arthroplasty: A Randomized Controlled Trial J.A. Singh, M.L. Mahowald, S. Noorbalaocchi .................................. 1534


Meetings in Rheumatology

.... xi